Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancer

Functional characterization of CHEK2 variants in a Saccharomyces cerevisiae system

(2019) Angeliki Delimitsou et al.   HUMAN MUTATION

Recurrent moderate‐risk mutations in Finnish breast and ovarian cancer patients

(2019) Anna Nurmi et al.   INTERNATIONAL JOURNAL OF CANCER

Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients

(2019) Allison W. Kurian et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification and analysis of CHEK2 germline mutations in Chinese BRCA1/2-negative breast cancer patients

(2018) Zhenhua Fan et al.   BREAST CANCER RESEARCH AND TREATMENT

Association Between CHEK2*1100delC and Breast Cancer: A Systematic Review and Meta-Analysis

(2018) Mingming Liang et al.   Molecular Diagnosis & Therapy

Validation of CZECANCA (CZEch CAncer paNel for Clinical Application) for targeted NGS-based analysis of hereditary cancer syndromes

(2018) Jana Soukupova et al.   PLoS One

Gene panel testing of 5589 BRCA1/2 -negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer

(2018) Jan Hauke et al.   Cancer Medicine

Germline pathogenic variants identified in women with ovarian tumors

(2018) Natalie J. Carter et al.   GYNECOLOGIC ONCOLOGY

Familial breast cancer and DNA repair genes: Insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing

(2018) Elodie Girard et al.   INTERNATIONAL JOURNAL OF CANCER

Classifying variants in the CHEK2 gene: the importance of collaboration

(2017) C. Espenschied et al.   EUROPEAN JOURNAL OF CANCER

Rare, protein-truncating variants in ATM , CHEK2 and PALB2 , but not XRCC2 , are associated with increased breast cancer risks

(2017) Brennan Decker et al.   JOURNAL OF MEDICAL GENETICS

Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer

(2017) Fergus J. Couch et al.   JAMA Oncology

Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women

(2017) Tom Walsh et al.   JAMA Oncology

Women at high risk of breast cancer: Molecular characteristics, clinical presentation and management

(2016) Zdenek Kleibl et al.   BREAST

Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results

(2016) Mary Pritzlaff et al.   BREAST CANCER RESEARCH AND TREATMENT

Genetic modifiers of CHEK2*1100delC-associated breast cancer risk

(2016) Taru A. Muranen et al.   GENETICS IN MEDICINE

Age- and Tumor Subtype–Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers

(2016) Marjanka K. Schmidt et al.   JOURNAL OF CLINICAL ONCOLOGY

Multigene testing of moderate-risk genes: be mindful of the missense

(2016) E L Young et al.   JOURNAL OF MEDICAL GENETICS

PALB2,CHEK2andATMrare variants and cancer risk: data from COGS

(2016) Melissa C Southey et al.   JOURNAL OF MEDICAL GENETICS

Breast cancer risk is similar for CHEK2 founder and non-founder mutation carriers

(2016) Tracey P. Leedom et al.   Cancer Genetics

Inherited Mutations in Women With Ovarian Carcinoma

(2016) Barbara M. Norquist et al.   JAMA Oncology

Gene-Panel Sequencing and the Prediction of Breast-Cancer Risk

(2015) Douglas F. Easton et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association of Germline CHEK2 Gene Variants with Risk and Prognosis of Non-Hodgkin Lymphoma

(2015) Ondrej Havranek et al.   PLoS One

CHK2 kinase in the DNA damage response and beyond

(2014) L. Zannini et al.   Journal of Molecular Cell Biology

The CHEK2 I157T Variant and Breast Cancer Susceptibility: A Systematic Review and Meta-analysis

(2012) Chuan Liu et al.   Asian Pacific Journal of Cancer Prevention

Response to DNA damage of CHEK2 missense mutations in familial breast cancer

(2012) Wendy Roeb et al.   HUMAN MOLECULAR GENETICS

Roles of Kruppel-associated Box (KRAB)-associated Co-repressor KAP1 Ser-473 Phosphorylation in DNA Damage Response

(2012) Chen Hu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Risk of Breast Cancer in Women With a CHEK2 Mutation With and Without a Family History of Breast Cancer

(2011) Cezary Cybulski et al.   JOURNAL OF CLINICAL ONCOLOGY

Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence

(2011) Ben Zhang et al.   LANCET ONCOLOGY

Structure and Activation Mechanism of the CHK2 DNA Damage Checkpoint Kinase

(2009) Zhenjian Cai et al.   MOLECULAR CELL

CHEK2*1100delC Genotyping for Clinical Assessment of Breast Cancer Risk: Meta-Analyses of 26,000 Patient Cases and 27,000 Controls

(2008) Maren Weischer et al.   JOURNAL OF CLINICAL ONCOLOGY

CHEK2 Mutations Affecting Kinase Activity Together With Mutations in TP53 Indicate a Functional Pathway Associated with Resistance to Epirubicin in Primary Breast Cancer

(2008) Ranjan Chrisanthar et al.   PLoS One